Tau or neurofilament light—Which is the more suitable biomarker for Huntington’s disease?

• Published in: PloS one Vol. 12; no. 2; p. e0172762
• Main Authors: Niemelä, Valter, Landtblom, Anne-Marie, Blennow, Kaj, Sundblom, Jimmy
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 27.02.2017; Public Library of Science (PLoS)
• Subjects: Adult; Aged; Alzheimer's disease; Alzheimers disease; Axons - metabolism; Biological markers; Biology and Life Sciences; Biomarkers; Biomarkers - cerebrospinal fluid; Brain research; care; Care and treatment; Cerebrospinal fluid; cerebrospinal-fluid biomarkers; Clinical trials; Cohort Studies; Correlation; csf; Cytoplasmic filaments; Diagnosis; Disease control; Disease Progression; Enzyme-Linked Immunosorbent Assay; Female; Genetic aspects; Humans; Huntington Disease - cerebrospinal fluid; Huntington Disease - diagnosis; Huntington Disease - genetics; Huntington's disease; Huntingtons disease; Light; Light levels; Male; Medicine and Health Sciences; Middle Aged; Multiple sclerosis; Mutation; natural-history; Neurochemistry; Neurodegeneration; Neurofilament Proteins - cerebrospinal fluid; Neurologi; Neurology; Neurosciences; Neurovetenskaper; pathology; Physiological aspects; protein; Proteins; Science & Technology - Other Topics; Studies; Tau protein; Tau proteins; tau Proteins - cerebrospinal fluid; Young Adult

Previous studies have suggested cerebrospinal fluid (CSF) levels of neurofilament light (NFL) and total tau are elevated in Huntington's disease (HD) and may be used as markers of disease stage. Biomarkers are needed due to the slow disease progression and the limitations of clinical assessment...